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Breast cancer cell line MCF7 
escapes from G1/S arrest induced 
by proteasome inhibition through 
a GSK-3β dependent mechanism
Elena Gavilán1, 2, Servando Giráldez3, Inmaculada Sánchez-Aguayo4, Francisco Romero3, 
Diego Ruano1, 2 & Paula Daza4
Targeting the ubiquitin proteasome pathway has emerged as a rational approach in the treatment of 
human cancers. Autophagy has been described as a cytoprotective mechanism to increase tumor cell 
survival under stress conditions. Here, we have focused on the role of proteasome inhibition in cell 
cycle progression and the role of autophagy in the proliferation recovery. The study was performed in 
the breast cancer cell line MCF7 compared to the normal mammary cell line MCF10A. We found that 
the proteasome inhibitor MG132 induced G1/S arrest in MCF10A, but G2/M arrest in MCF7 cells. The 
effect of MG132 on MCF7 was reproduced on MCF10A cells in the presence of the glycogen synthase 
kinase 3β (GSK-3β) inhibitor VII. Similarly, MCF7 cells overexpressing constitutively active GSK-3β 
behaved like MCF10A cells. On the other hand, MCF10A cells remained arrested after MG132 removal 
while MCF7 recovered the proliferative capacity. Importantly, this recovery was abolished in the 
presence of the autophagy inhibitor 3-methyladenine (3-MA). Thus, our results support the relevance 
of GSK-3β and autophagy as two targets for controlling cell cycle progression and proliferative 
capacity in MCF7, highlighting the co-treatment of breast cancer cells with 3-MA to synergize the 
effect of the proteasome inhibition.
Cancer development is often due to perturbations in the cell cycle that lead to unlimited proliferation 
and cancer cells are usually chemo-resistant1–3. Understanding how cells die is critical to develop new 
strategies in order to try to improve the therapies to kill tumor cells.
The ubiquitin-proteasome pathway is responsible for the degradation of most poly-ubiquitinated pro-
teins including proteins that control cell cycle progression, death cell and in general all the proteins that 
confer normal homeostasis levels. Therefore, targeting the ubiquitin-proteasome pathway has emerged 
as a rational approach in the treatment of human cancers in the last years4–6. Moreover, because cancer 
cells are generally more sensitive than normal cells to the inhibition of proteasome activity7–9, proteasome 
inhibitors are being used in anti-cancer therapy.
On the other hand, autophagy constitutes one of the major responses of cells to external or inter-
nal stimuli. Autophagy is a cellular process that engulfs organelles and cytoplasmic contents to digest 
and recycle these materials to sustain cellular metabolism10–12. In addition to provide a basic catabolic 
function, autophagy is also used by the cell to cope with stressful conditions to improve survival13. As 
any other major phenomenon of cell biology, autophagy can be perturbed in cancer cells and it is also 
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modulated by anticancer chemo-therapies14,15. In this sense, the role of autophagy is controversial and it 
seems to be both tumor cell line-and treatment-dependent. The link between autophagy and cell death 
is still ambiguous, and autophagy may serve as a tumor suppressor mechanism, directing the cells to 
self-destruction, or as an oncogenic process and hence avoiding cell death14–18. Remarkably, autophago-
somal markers are overexpressed in breast carcinomas with different cytosolic patterns and prognosis19. 
Thus, a better comprehension of the role of autophagy in cancer cells is mandatory for chemo-therapy 
development. In addition, glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine kinase that 
has been extensively studied because of its roles in several physiological disorders including cancer20–22 
and many data support a function for this protein as a cell cycle-key regulator23.
Here we have focused on both the effect of proteasome inhibition on cell cycle progression, investi-
gating the role of GSK-3β, as well as the role of autophagy on cell proliferation under proteasome stress. 
We demonstrated that GSK-3β signaling is involved in G2/M arrest in MCF7 cell line under proteasome 
stress and identified autophagy as a cellular mechanism to evade cell cycle arrest in these cells. The lethal 
effect of MG132 on MCF7 cells is remarkably boosted by the inhibition of autophagy. Present findings 
support that blockade of autophagy may enhance the therapeutic effects of proteasome inactivation in 
the treatment of breast cancer.
Results
Proteasome inhibition arrested the cell cycle at G1 or G2/M phases in MCF10A and MCF7, 
respectively. To evaluate the effect of the proteasome inhibitor MG132 on the cell cycle we treated 
both MCF10A, a normal mammary cell line, and MCF7, a breast tumor cell line, with MG132 1 and 
5 μM for 24 hours and afterwards, cells were analyzed by flow cytometry. As shown in Fig. 1a, it can be 
noted that while in MCF10A cells both doses caused a significant arrest in G1 (P = 0.002), the tumor 
cell line MCF7 seemed to overtake the G1 checkpoint and were mainly arrested in the G2/M phase 
(Fig. 1a,b).
To further confirm these data we analyzed by western blots the expression of two specific cell cycle 
proteins: cyclin E (G1/S) and cyclin B (G2/M). Proteasome inhibition induced cyclin E accumulation, in 
normal but not in tumor cell line. By contrast, cyclin B accumulated in tumor cells, but not in the normal 
mammary epithelial cells, supporting flow cytometry data (Fig. 1c). Remarkably, proteasome inhibition 
induced significant transcriptional expression of cyclin E in MCF10A but not in MCF7 cells (P = 0.002; 
Fig. 1d). We further analyzed the level of phosphorylation of the Rb protein. As shown in Fig. 1e, the 
amount of both Rb and phospho-Rb was similar in both cell types under control conditions. However, 
MG132 treatment produced a significant decrease in the Rb/phospho-Rb ratio in normal mammary 
versus tumor cells (P = 0.02). Taken together, these results show that under proteasome stress the tumor 
cell line MCF7 is overriding the G1 checkpoint and progressing through the S phase to finally arrest in 
the G2/M phase.
GSK-3β inhibition rescued MCF10A cells from G1/S arrest induced by proteasome inhibi-
tion. We have previously shown that acute proteasome inhibition produced a consistent and dose 
dependent inhibition of the GSK-3β protein in the tumor cell line MCF7 but not in the normal mam-
mary cell line MCF10A24. Because growing evidence indicated that GSK-3β can be, directly or indirectly, 
involved in cell cycle progression we wondered whether cell cycle behavior of tumor cells under protea-
some stress could be dependent, at least in part, on GSK-3β signaling. To address this issue, we treated 
the cell line MCF10A with 1 μM of MG132 for 24 hours, in the absence or in the presence of 20 μM of 
the GSK-3β inhibitor VII. As show in Fig. 2a and B, GSK-3β inhibitor VII overtook the G1/S arrest of 
MCF10A cells treated with MG132, and detained cell cycle at G2/M phase (P = 0.001), similarly as tumor 
cells did in the presence of MG132 alone (see Fig.  1a). Moreover, western blot analysis revealed that 
expression of cyclins E and B in the presence of both MG132 and GSK-3β inhibitor VII (Fig. 2c) was sim-
ilar to that observed in MCF7 cells in the presence of MG132 alone (see Fig. 1c). In this sense, the cyclin 
E/cyclin B ratio was high in MCF10A cells treated with MG132 but low in co-treated MCF10A cells, 
similarly to MG132 treated MCF7 cells (Fig.  2c right). To go further, we transfected MCF7 cells with 
pCDNA3-HA-GSK-3β-S9A, that codifies a constitutively active form of GSK-3β, in order to enhance the 
level of active GSK-3β protein in the tumor cells. As it is shown in Fig. 2d, western blot analysis revealed 
that decreased expression of cyclin E induced by proteasome inhibition in MCF7 cells was abolished 
in pCDNA3-HA-GSK-3β-S9A transfected cells. Similarly, increased cyclin B expression was partially 
reverted in MCF7 transfected cells, as well as the G2/M arrest (Fig. 2d right and Supplementary Fig S1). 
Thus, these data strongly support that differences in the cell cycle behavior between both cell lines, 
induced by proteasome inhibition, are mediated at least in part, by GSK-3β signaling.
Tumor cell line MCF7 recovered the proliferative capability after removing MG132 while 
MCF10A cells remained arrested. Based on the different behavior induced by proteasome inhibi-
tion in both cell types, we wondered whether molecular and cellular differences could affect the prolif-
erative capability. To address this issue, we analyzed for a week the growing rate of both cell types after 
removing MG132 (1 and 5 μM). As shown in Fig. 3a,b, control cells were growing properly, while MG132 
treatment drastically affected cell proliferation in both cell lines. The higher dose of MG132 caused sim-
ilar effects on both cell types and neither proliferation nor recovery was observed after a week. However, 
www.nature.com/scientificreports/
3Scientific RepoRts | 5:10027 | DOi: 10.1038/srep10027
Figure 1. Effect of proteasome inhibition on cell cycle in MCF10A and MCF7 cells. a. Cell cycle 
distribution of both cell lines following 24 hours of MG132 treatment (1 and 5 μM). b. Quantification of 
cell cycle distribution indicating the % of cells detected in each stage (G1 and G2/M). Data are expressed as 
a percentage ± SD of three independent experiments. c. Representative western blots corresponding to the 
expression of cyclins E and B following MG132 (1 and 5 μM) for 24 hours. d. RT Real-time-PCR of cyclin E 
in treated and non-treated cells with 5 μM of MG132 for 24 hours. Data are expressed as a percentage ± SD 
of three independent experiments. e. Representative western blots of total and phospho-(Ser795) Rb in basal 
and 24 hours after 5 μM MG132 in both cell lines. It is shown also the quantification of the pRb/Rb ratio. 
Data are expressed as relative units of the optical density (OD) ± SD of three independent experiments. 
*significant differences compared to controls. # significant differences between MCF10A and MCF7 cells. 
Gels were run in parallel and under the same experimental conditions.
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cellular response to the lower dose of MG132 was quite different in both cell types. While in MCF10A 
cells, proliferation was very limited (around 10% of control cell number at the end of the assay), the 
tumor cells started to proliferate 3 to 5 days after MG132 removal, reaching up to the 60% of control cell 
number at the end of the assay (Fig. 3a,b, respectively). These results indicated that tumor cells escaped 
from the cell cycle arrest induced by MG132 treatment, while MCF10A did not.
Figure 2. Cell cycle behavior of both cell lines after GSK-3 β modulation. a. Cell cycle distribution 
of MCF10A cells following 24 hours of 1 μM MG132 and 20 μM GSK-3β inhibitor VII independently or 
combined. b. Quantification of the cycle distribution indicating the % of cells detected in each stage (G1 and 
G2/M). Data are expressed as a percentage ± SD of three independent experiments. c. Representative western 
blots corresponding to the expression of cyclins E and B in MCF10A cells in the presence of both MG132 
and GSK-3β inhibitor VII, independently or combined, and a diagram of the cyclin B/E ratio.  
d. Representative western blot of cyclins E and B in GSK-3β -S9A-transfected MCF7 cells treated with 1 μM 
MG132, and a diagram of the cyclin B/E ratio. The quantitative fold change in cyclin E or B was determined 
relative to the loading control. *significant differences compared to controls. Gels were run in parallel and 
under the same experimental conditions.
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Proteasome stress induced early autophagy activation in MCF7 cells. Since cell recovery after 
MG132 treatment was different in both cell lines, we performed morphological, ultrastructural and bio-
chemical analysis after removing MG132. The study was carried out just along three days after MG132 
withdrawal. As expected24, proteasome inhibition (MG132 1 μM for 24 hours) induced the formation 
of cytosolic aggregates in MCF10A cells, while induced cytosolic vacuoles in MCF7 cells (Fig.  4a). In 
order to test whether these cytosolic vacuoles corresponded to autophagosomes, we performed immu-
nofluorescence assay with the autophagosomal marker LC3. As shown (Fig. 4b upper panel), proteasome 
inhibition induced early formation of perinuclear punctated structures immunopositive for LC3 in tumor 
cells. The presence of these structures diminished in a time dependent manner during the recovery 
period. By contrast, in MCF10A cells, similar punctated structures were observed but they appeared 
during the recovery period (Fig.  4b lower panel). Quantification of LC3 immunopositive cells in both 
MCF10A and MCF7 lines is shown in Fig. 4c. These data suggest that autophagy activation induced by 
proteasome inhibition started earlier in MCF7 than in MCF10A cells. This idea was corroborated by 
the staining assay with the acidotropic dye LysoTracker that labels acidic compartments such as lyso-
somes and autophagosomes. The staining pattern was similar to that observed for LC3 in both cell types 
(Fig. 4d,e).
On the other hand, MCF10A cells augmented in size and diminished in number after MG132 elimi-
nation. Moreover, the yuxtanuclear aggregates were disappearing at the same time that cytosolic vacuoles 
were appearing throughout the recovery period, showing most of them a highly vacuolated cytoplasm. 
This was also confirmed by ultrastructural analysis by TEM in ultrathin sections. As shown in Fig. 5a, 
cytoplasmic vacuoles in MCF10A cells increased in size, in a time dependent manner, filling the entire 
cytosolic surface and surrounding the cytoplasmic aggregates in some cells. Some cytosolic vacuoles 
observed in MCF10A cells had the appearance of autophagic vacuoles as judged by the double membrane 
and the heterogeneous content, supporting immunofluorescence data. In addition, we also observed large 
empty vacuoles in both cell types which resembled senescent vacuoles. In fact, the proportion of senes-
cent cells, determined by SA-β-gal assay, was significantly higher in MCF10 than in MCF7 cells 48 hours 
following MG132 removal (P = 0.0003; Supplementary Fig S2).
To better characterize the autophagy activity, we performed western blot analysis of both LC3 II and 
p62 proteins. In MCF10A cells, MG132 did not modify the amount of LC3 II, but increased the content 
of p62 even 24 hours after MG132 elimination, supporting absence of autophagy activation (Fig.  5b). 
However, during the recovery period LC3 II increased at the same time that p62 decreased, supporting 
late autophagy activation. In contrast, in MCF7 cells, MG132 increased basal autophagic activity with 
minor p62 accumulation. Remarkably, a dramatic LC3 II accumulation occurred 48 hours following 
MG132 removal, which returned to basal level 24 hours later (Fig. 5b). This might be due to a decrease 
in the autophagy flux in MCF7 (Supplementary Fig S3). However, we cannot rule out other possibilities. 
Importantly, tumor cells showed a long-term GSK-3β inhibition during the recovery phase that was 
not observed in the MCF10A line. Taken together, these results strongly support that early autophagy 
activation in addition to GSK-3β chronic inhibition might be crucial for tumor cell recovery under 
proteasome stress.
Recovery of the proliferative capacity was dependent on early autophagy activation. To 
evaluate the role of early autophagy activation in the recovery of the proliferative capacity of cells under 
proteasome stress, we treated MCF7 and MCF10A cells with MG132, 3-MA or both for 24 hours and, 
after elimination of the corresponding compounds, we performed proliferation assays. As shown in 
Fig.  6a, the treatment with the autophagy inhibitor 3-MA did not affect the cell proliferation rate nei-
ther in MCF10A nor in MCF7 cells. On the other hand, MG132 strongly affected cell proliferation 
in MCF10A whereas MCF7 cells were able to proliferate reaching up to 57% of control cell number. 
Figure 3. Analysis of cell recovery following proteasome inhibition. It is shown the proliferative capacity 
of MCF10A (a) and MCF7 (b) cells during a week after removing MG132 (1 and 5 μM). Data are expressed 
as average ± SD of cell number. Note MCF7 recovery following 1 μM of MG132, while this is not observed in 
MCF10A cells.
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Figure 4. Study of the proteasome inhibition and recovery in MCF7 and MCF10A cells. a. Structural 
study of both cell lines 24, 48 and 72 hours after MG132 withdrawal. Note the high vacuolization level in 
MCF10A cells. Scale bar 10 μm. b. Control MCF7 and MCF10A cells, treated with MG132 1 μM for 24 hours 
and recovered 48 and 72 hours later were stained for LC3 and DNA. In the merge, LC3 staining is shown in 
green and DNA in blue. Scale bar 10 μm. c. Quantification of LC3 positive cells from B. Cells were randomly 
selected from the acquired image and counted. The cells with more than five dots of specific green signal 
were considered to be LC3 positive. n = number of cells analyzed. d. Confocal microscopy of LysoTracker 
Green localization in MCF7 and MCF10A cells treated as in B. Lt: LysoTracker, Bf: Bright field. Scale bar 
5 μm. e. Quantification of LysoTracker positive cells from D. Cells were randomly selected from the acquired 
image and counted. n = number of cells analyzed. R48h and R72h represent data from 48 and 72 hours after 
MG132 release.
www.nature.com/scientificreports/
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However, co-treatment of MG132 and 3-MA abolished cell proliferation in the tumor cell line, but 
growth rate was not modified in the normal mammary cell line (compared to MG132 treatment). In 
order to confirm this issue we performed clonogenic assays for fifteen days using the same experimen-
tal conditions. As it is shown in Fig.  6b, the proliferative capability of both cell lines was affected by 
proteasome inhibition, being the normal mammary cells the most altered. Nevertheless, the number 
of MCF7 cell colonies diminished significantly (P = 0.0001) 15 days after co-treatment of MG132 and 
3-MA (around 40% compared to MG132 treated MCF7 cells), while in the MCF10A cells the survival 
fraction remained constant, suggesting that early autophagy activation is relevant for the recovery of 
cell proliferation in the tumor cell line MCF7, while late autophagy activation is not so profitable for 
MCF10A cells. We further analyzed at the molecular level the effect of MG132 and 3-MA co-treatment 
in the tumor cell line MCF7. As shown in Fig. 6c, both proteasome and autophagy inhibition induced 
a significant increase in the content of poly-ubiquitinated proteins (P = 0.0001). Moreover, co-treatment 
modified the profile of poly-ubiquitinated protein accumulation, indicating that 3-MA was efficiently 
inhibiting autophagy in these cells. The clearance of poly-ubiquitinated proteins was significantly delayed 
in co-treated MCF7 cells, compared to cells treated with MG132 alone (P = 0.0002; Fig.  6d). This dif-
ference could be attributable to the early block of autophagy produced by 3-MA. Indeed, at 24 hours of 
co-treatment we observed the accumulation of LC3 I but not of LC3 II, supporting autophagy inhibition. 
Importantly, autophagy activity was restored in co-treated MCF7 cells during the recovery phase as judge 
by the level of LC3 II, which was observed 24 hours later than in MCF7 cells treated with MG132 alone 
(compare Fig. 5b upper panel with Fig. 6c lower panel). Taken together, these findings strongly support 
that basal autophagy activity in the breast cancer cell line MCF7 represents a mechanism to evade cell 
death induced by proteasome inhibition.
GSK-3β inhibition partially recovered the proliferative capacity of MCF10A cells under pro-
teasome stress. As showed above, GSK-3β inhibition rescued MCF10A cells from G1/S arrest 
induced by MG132 (see Fig.  2). Importantly, as we and other have previously demonstrated pharma-
cological inhibition of GSK-3β activity induced early autophagy activation24,25. In order to test whether 
this inhibition in MCF10A cells would mimic MCF7 proliferative behavior following 24 hours of MG132 
Figure 5. Ultrastructural and biochemical analysis of autophagy resolution during proteasome 
inhibition recovery. a. TEM analysis of MCF10A (upper panel) and MCF7 cells (lower panel) following 
24 hours of proteasome inhibition and 24, 48 and 72 hours after removing MG132. Scale bar 4 μm. b. 
Representative western blots of specific autophagic markers (LC3 and p62) and phosphorilated GSK-3β 
protein expression in MCF10A (left) and MCF7 cells (right), following 24 hours of proteasome inhibition 
and 24, 48 and 72 hours after removing MG132. Gels were run in parallel and under the same experimental 
conditions.
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treatment, we inhibit GSK-3β and performed proliferation assays. Treatment with the GSK-3β inhibi-
tor for 168 hours did not affect cell proliferation rate, while proteasome inhibition deeply impaired cell 
growth even 168 hours after drug removal (Fig. 7a). However, when MCF10A cells were simultaneously 
treated with both inhibitors for 24 hours, and cells were allowed to grow in the presence of the GSK-3β 
VII inhibitor after MG132 elimination, cell proliferation began to recover reaching up to 20% of control 
cell number 168 hours later (Fig. 7b). Thus, these data provide strong evidence supporting that chronic 
GSK-3β inhibition in addition to early autophagy activation could be responsible for the proliferation 
recovery of both breast epithelial cells following proteasome inhibition, a mechanism that could be essen-
tial for cell survival.
Discussion
Breast cancer stands second in cancer-related mortality of women26,27. In the present work we have 
investigated the role of proteasome inhibition on cell cycle progression and cell proliferation in both the 
human breast cancer cell line MCF7 and the normal mammary cell line MCF10A. The most relevant 
findings are summarized as follow: i) tumor cells ignored the G1/S but arrested in the G2/M checkpoint 
following proteasome inhibition, whereas the normal mammary cells arrested in the G1/S checkpoint; 
ii) GSK-3β inhibition was necessary to override the G1 checkpoint under proteasome stress; iii) tumor 
cells recovered the proliferative capability three days after MG132 was removed, while MCF10A did not; 
iv) tumor cells activated proteasome inhibition induced autophagy earlier than MCF10A; and v) early 
autophagy activity was necessary for the recovery of cell proliferation in the tumor cell line MCF7. Taken 
together our results support that GSK-3β signaling and autophagy activity are two related processes that 
confer adaptive advantages to cell survival.
Figure 6. Comparative study of the effect of the co-treatment with proteasome and autophagy 
inhibitors. a. Proliferative capacity of MCF10A (left) and MCF7 cells (right) during a week following 
24 hours of MG132 and 3-MA treatment, independently or combined. Note that MCF7 cells do not recover 
the proliferative capacity with the co-treatment, compared with MCF7 cells treated only with MG132. 
b. Clonogenic assay of MCF10A and MCF7 cells for fifteen days after MG132 and 3-MA withdrawal, 
independently or combine. Data were similar to those obtained with the growth curves. c. Representative 
western blots of total poly-ubiquitinated proteins in MCF7 cells 24, 48 and 72 hours after removing MG132 
(left) or after co-treatment removal (right). It is also shown a representative western blot of LC3 protein 
expression during co-treatment recovery. d. Quantification of total poly-ubiquitinated proteins in MCF7 
cells as shown in c. Data are expressed as average ± SD of relative units of three independent experiments. 
*significant differences compared to control cells. # significant differences between MG132-treated and  
co-treated cells. Gels were run in parallel and under the same experimental conditions.
www.nature.com/scientificreports/
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Cyclins are the regulators of the cell cycle28–31. The cyclin E binds to the G1 phase cyclin-dependent 
kinase Cdk2 controlling the G1 to S phase transition in cell cycle, which is the rate-limiting step for 
proliferation32. Our results demonstrated that, under proteasome stress, cyclin E accumulated exclusively 
in MCF10A cells indicating arrest at the G1/S phase. Indeed, the pRb/Rb was significantly lower in these 
cells than in tumor cells, supporting that cyclin E/Cdk2 complex was not active in MCF10A. On the 
other hand, cyclin B levels raise during the S and G2 phases for entering M phase and subsequently cyc-
lin B must be degraded by the proteasome in order to finish mitosis and enter G1 phase again33. In this 
sense, we demonstrated that proteasome inhibition caused accumulation of cyclin B only in MCF7 cells, 
supporting arrest at the G2/M phase. Moreover, the analysis of phospho-Rb revealed that in these cells 
remained always a significant amount of this phosphorylated protein, leading to progression through 
the G1 phase of the cell cycle34,35. These results point that the tumor cell line MCF7 fails to comply with 
G1 checkpoint, which was then overpassed under stressful conditions, allowing the cells to go further.
In addition, GSK-3β is also an important regulator of several processes, including cell cycle progres-
sion as well as proliferation and cell death22,36. In this sense, cyclin E levels are negatively regulated by 
GSK-3β, which phosphorylates it promoting its proteasomal degradation37,38. In fact, MCF10A cells have 
a high GSK-3β activity and proteasome inhibition increased the cyclin E/cyclin B ratio, arresting the cells 
in the G1/S phase. However, GSK-3β activity in MCF7 is lower than in MCF10A, and MG132 decreased 
the cyclin E/cyclin B ratio being the cells then arrested at G2/M. Remarkably, these features were caus-
ally related because of proteasome inhibition in MCF10A cells decreased the cyclin E/cyclin B ratio and 
arrested cells in the G2/M phase, as MCF7 cells did, when GSK-3β was pharmacologically inhibited. 
Similarly, proteasome inhibition in MCF7 cells that overexpressed a constitutive active form of GSK-3β, 
increased the cyclin E/cyclin B ratio as did MCF10A cells. Taken together these data indicated that 
under proteasome stress cyclin E degradation is depending on GSK-3β activity, suggesting that chronic 
inhibition of GSK-3β could be responsible, at least in part, of the cell cycle alteration in these tumor cells.
An important issue remaining is to know how tumor cells can progress when proteasome is inhib-
ited. In this sense, proteasomal degradation of cyclin E is mandatory for cell cycle progression. Thus, 
Figure 7. Analysis of MCF10A cell recovery following proteasome inhibition with MG132 and in the 
presence of the GSK-3β inhibitor VII. a. Representative images of MCF10A cells in control situation 
and with different treatments at the end of the assay. Note the difference in cell number in MG132 (24 h) 
and MG132 (24 h) + GSK-3β inhibitor VII (present during treatment and recovery). Scale bar 30 μm b. 
Proliferative capacity of MCF10A cells during a week following 24 hours of MG132 1 μM and GSK-3β 
inhibitor VII 20 μM treatment, independently or combined. Note that cells treated with MG132 do not 
recover the proliferative capacity while co-treated cells (MG132 + GSK-3β inhibitor VII) restored cell 
proliferation rate.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:10027 | DOi: 10.1038/srep10027
additional pathways for the degradation of this protein must be operative in these tumor cells under 
proteasome stress. We speculate about the possibility that autophagy could be involved in this process. 
This speculation is based on the fact that MCF7, but not MCF10A cells, early increased the autophagy 
activity under proteasome stress, a process that was mediated by the inhibition of GSK-3β24,25. Here, we 
demonstrated that normal mammary cells behaved like tumor cells when GSK-3β was pharmacologically 
inhibited. In this way, under proteasome stress situation cyclin E accumulated in MCF10A because the 
proteasome was inhibited, whereas in the tumor cells MCF7 cyclin E did not accumulate because it might 
be being degraded by the autophagy pathway. It is noticeable, that cyclin B accumulated in MCF7 cells, 
indicating that proteasome was efficiently inhibited also in these cells. However, further experiments will 
be necessary to evaluate the potential role of autophagy in cyclins degradation.
Because cancer cells are generally more sensitive than normal cells to the inhibition of proteasome 
activity, proteasome inhibitors are being used in anti-cancer therapy. Furthermore, our results also 
demonstrated that cell proliferation was higher in tumor than in normal mammary cells. Importantly, 
we have previously demonstrated that acute proteasome inhibition produced a huge autophagy induction 
accompanied by a higher mortality rate in MCF7 than in MCF10A cells24. However, here we observed 
that tumor cells recovered better than MCF10A cells from proteasome inhibition. Indeed, the normal 
mammary cells did not proliferate at any doses used in the study, whereas MCF7 cells started to pro-
liferate 3 days after removal of the lower dose of MG132. Our data also revealed that cell recovery was 
dependent on early autophagy activation and chronic GSK-3β inhibition. In fact, under proteasome 
stress tumor cells early activated autophagy, chronically inhibited GSK-3β and recovered cell prolifer-
ation, whereas MCF10A cells did not. However, when MCF10A cells were treated with MG132 in the 
presence of the GSK-3β inhibitor VII, they early activated autophagy24,25 and began to proliferate, resem-
bling MCF7 behavior.
On the other hand, late autophagy activation induced by proteasome inhibition in normal mammary 
cells might be mediated by a GSK-3β-independent mechanism. In this sense, the unfolfed protein response 
might be an alternative39. This mechanism could be also operative in MCF7 cells. Importantly, induction 
of autophagy through ATF4 has been proposed as a relevant resistance mechanism to Bortezomib treat-
ment in breast cancer cells40 and we have previously reported strong up-regulation of ATF4, and mostly 
CHOP, in MCF7 but not in MCF10A cells, 24 hours after proteasome inhibition24. Thus, we speculate that 
early activation of autophagy could be mostly dependent on GSK-3β inhibition and ATF4 expression, 
whereas late autophagy induction could be more dependent on the unfolded protein response.
In summary we provide solid evidence supporting that the simultaneous targeting of the proteasome 
and the autophagy machinery may represent an alternative for breast cancer treatment in order to pro-
mote a lethal synergic effect caused by the inhibition of both proteolytic systems.
Methods
Cells and culture conditions. The study was carried out in an ER + human epithelial breast cancer 
cell line, MCF7, and in a human epithelial normal mammary cell line, MCF10A (American Type Culture 
Collection). MCF7 cells were cultured in DMEM/Ham’s F12 (1/1) medium (PAA Laboratories) supple-
mented with 10% (v/v) foetal bovine serum (FBS) (Gibco), 2 mM L-glutamine, 50 μg/ml streptomycin 
and 50 U/ml penicillin (Sigma-Aldrich). The human normal mammary epithelial cells MCF10A were 
grown in DMEM/Ham’s F12 (1/1) medium (PAA Laboratories) supplemented with 10% (v/v) horse 
serum (Gibco), 2 mM L-glutamine, 50 μg/ml streptomycin, 50 U/ml penicillin, 2.5 mg/ml insulin, 150 μg/
ml cholera enterotoxin (Sigma-Aldrich), 2.5 mg/ml hydrocortisone and 50 μg/ml epidermal growth fac-
tor (Calbiochem). Both cell lines were maintained at 37 °C in a humidified atmosphere with 5% CO2. 
Cells were routinely subcultured and they were always in exponential growth phase when used for exper-
iments. Each experiment was independently performed at least in triplicate.
Treatments and drugs. Both cell lines were treated in parallel with the reversible proteasome inhibitor 
MG132 (Sigma-Aldrich) at different doses. Cells were also treated with 1 mM of 3-MA (Sigma-Aldrich), 
an autophagy inhibitor and with 20 μM of GSK-3β inhibitor VII (Calbiochem). Treatments were carried 
out alone or in combination for 24 hours.
Cell proliferation. Growth curves. Cells were plated in triplicate at a 60,000 cells/cm2 density in 
35 mm dishes. Cells were allowed to adhere for two days and then they were treated with the different 
doses of MG132 (1 and 5 μM), 3-MA (1 mM) and GSK-3β inhibitor VII (20 μM) for 24 hours. After 
treatment, cells were washed twice with PBS and fresh medium was added to allow the cells to recover. 
When cells were treated with GSK-3β inhibitor VII, this was always present till the end of the assay to 
ensure a sustained inhibition of GSK-3β protein. The dishes were placed at the incubator for 168 hours; 
every 24 hours cells were trypsinized and counted with a haemocytometer. Cell viability was assessed 
by trypan blue exclusion test. Cells from dishes were counted by triplicate for each dose and in three 
independent experiments.
Clonogenic assays. Cells were trypsinized, counted and plated in triplicate in 12 mm dishes. Cell num-
bers seeded were 500 and 1,000 for controls and treatments respectively. Then, they were allowed to 
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adhere for one day and they were treated with 1 μM MG132 and 1 mM 3-MA for 24 hours. After treat-
ment, cells were washed twice with PBS and fresh medium was added. Cells were allowed to form 
colonies for 15 days. They were stained with methylene blue in 4% acetic acid for 30 min and washed 
with distilled water. Colonies with at least 50 cells were considered and scored using a colony counter.
Western blotting. Immunoblots were done as previously described41. Briefly, proteins were loaded 
on a 10% or 12% polyacrylamide gel for electrophoresis (SDS–PAGE; Bio-Rad) and then transferred 
to a nitrocellulose membrane (Hybond-C Extra; Amersham). After blocking, membranes were incu-
bated overnight at 4 °C, with the following primary antibodies: (i) rabbit polyclonal antibodies against: 
phospho-GSK-3β(S9) (Cell Signaling), Ubiquitin (Dako) , LC3 (Novus Biologicals) and p62 (Cell 
Signaling); (ii) mouse monoclonal antibodies against: β-actin (Sigma-Aldrich), GSK-3-clone 4G-1E 
(Millipore), cyclin E (HE12) and cyclin B1 (GNS1) from Santa Cruz Biotech., GSK-3β (BD Biosciences) 
and HA (anti-HA-peroxidase, Roche). Then, membranes were incubated with the appropriate secondary 
antibody (Dako) horseradish-peroxidase-conjugated, at a dilution of 1/10000 and developed using the 
ECL-plus detection method (Amersham) and the ImageQuant LAS 4000 MINI GOLD (GE Healthcare 
Life Sciences). For quantification, the optical density of individual bands was analyzed using PCBAS 
2.08 software (Raytest Inc, Germany), and the optical density of each band was normalized relative to 
the optical density of β-actin.
Morphological and ultrastructural studies. Cell monolayers were fixed in 2.5% (v/v) glutaralde-
hyde in 0.1 M sodium cacodylate-HCl buffer pH = 7.4 for 1h at 4 °C. Cells were rinsed in cacodylate 
buffer twice and incubated for 1h at 4 °C in 1% (v/v) OsO4/1% (w/v) K4Fe(CN)6 in cacodylate buffer 
pH = 7.4. Cells were rinsed again in cacodylate buffer and finally in distilled water. Then, cells were 
stained with 1% (w/v) aqueous uranyl acetate for 2h at 4 °C. After washing with distilled water, they 
were dehydrated through increased graded ethanol series and embedded in Epon resin 812. Ultrathin 
sections were stained with lead citrate for 5 min for transmission electron microscopy (TEM) (Philips 
CM10). Toluidine-blue stained 0.5 μm semithin sections were used as control for optical microscopy 
(Leica DME) and images were acquired 100X. All reagents were purchased from Sigma-Aldrich.
RNA extraction and reverse transcription. For PCR analysis, total RNA was extracted using the 
Tripure Isolation Reagent (Roche, Mannheim, Germany), according to the instructions of the manufac-
turer. The recovery of RNA was similar between MCF10A and MCF7 cells. Reverse transcription was 
performed using random hexamers primers exactly as previously described24.
Real-time RT-PCR. cDNAs were diluted in sterile water and used as template for the amplification 
by the polymerase chain reaction. Amplification of each specific gene product was performed using 
the ABI Prism 7000 sequence detector (Applied Biosystems) and TaqMan probes designed by Applied 
Biosystems. The cDNA levels of the different cell types were determined using two different housekeepers 
(GAPDH and β-actin). The amplification of the housekeepers was done in parallel with the gene to be 
analyzed. Similar results were obtained using both housekeepers. Thus, the results were normalized using 
both β-actin and GAPDH expression. Threshold cycle (Ct) values were calculated using the software 
supplied by Applied Biosystems.
Immunofluorescence and LysoTracker assay. MCF7 and MCF10A cells were grown on coverslips, 
treated as indicated in the figure, fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton 
X-100. Immunostaining, using a polyclonal anti-LC3 (Novus Biologicals) antibody, and counterstain-
ing with DAPI to visualize the nuclei, was carried out according to standard protocols. Epifluorescence 
microscopy was performed using a Leica microscope. For LysoTracker assay, living cells, treated as indi-
cated, were exposed to pre-warmed medium containing 50 nM of LysoTracker Green DND-26 for 30 min 
at 37 °C, washed with fresh medium and observed using a Zeiss confocal microscope.
Flow cytometry analysis. MCF7 and MCF10A cells were treated with MG132 and GSK-3β inhibitor 
VII at the indicated doses for 24 hours. Cells were harvested by trypsinization and collected by centrifu-
gation. Cells were washed once with PBS and fixed in 5 ml ethanol 70% at 4 ºC. Cells were washed once 
with PBS/1%BSA and then incubated with 1 ml of PBS/1%BSA containing 50 μg/ml propidium iodide 
and 0.1 mg/ml RNAse for 1h at room temperature. Cells were analyzed for DNA content by flow cytom-
etry using a LSR Fortessa from Becton-Dickinson and doublet discrimination was performed. The data 
were analysed using the BD FACSDiva software.
Transient transfection experiments. MCF7 cells were transiently transfected by electroporation 
with pCDNA3-HA GSK-3βS9A (Addgene) or empty vector (10 μg), incubated or not with MG132 (1 μM, 
Boston Chemical), and harvested 24 hours later.
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Statistical analysis. Data were expressed as mean ± SD. The comparison between both cell types was 
done by two-tailed t test. The significance was set at 95% of confidence. Statistical analysis was done 
using the Statgraphics plus (v 3.1) program (Warrenton, VA, USA).
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